Younossi ZM - Search Results

1

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Anstee QM, et al. Among authors: younossi zm. Hepatology. 2019 Nov;70(5):1521-1530. doi: 10.1002/hep.30842. Epub 2019 Aug 19. Hepatology. 2019. PMID: 31271665

2

Nonalcoholic fatty liver disease: an agenda for clinical research.

Younossi ZM, Diehl AM, Ong JP. Younossi ZM, et al. Hepatology. 2002 Apr;35(4):746-52. doi: 10.1053/jhep.2002.32483. Hepatology. 2002. PMID: 11915019 Review. No abstract available.

3

Non-alcoholic fatty liver disease: an overview.

Mulhall BP, Ong JP, Younossi ZM. Mulhall BP, et al. Among authors: younossi zm. J Gastroenterol Hepatol. 2002 Nov;17(11):1136-43. doi: 10.1046/j.1440-1746.2002.02881.x. J Gastroenterol Hepatol. 2002. PMID: 12453271 Review.

4

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Poynard T, et al. Hepatology. 2003 Jul;38(1):75-85. doi: 10.1053/jhep.2003.50267. Hepatology. 2003. PMID: 12829989 Clinical Trial.

5

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group. Afdhal NH, et al. Gastroenterology. 2004 May;126(5):1302-11. doi: 10.1053/j.gastro.2004.01.027. Gastroenterology. 2004. PMID: 15131791 Clinical Trial.

6

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group. Pockros PJ, et al. Hepatology. 2004 Dec;40(6):1450-8. doi: 10.1002/hep.20482. Hepatology. 2004. PMID: 15565613 Clinical Trial.

7

Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.

Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM. Ong JP, et al. Among authors: younossi zm. Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820. Obes Surg. 2005. PMID: 15826462

8

Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery.

Srivastava S, Younossi ZM. Srivastava S, et al. Among authors: younossi zm. Hepatology. 2005 Aug;42(2):490-2. doi: 10.1002/hep.20782. Hepatology. 2005. PMID: 15977205

9

Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis.

Younossi ZM, Gorreta F, Ong JP, Schlauch K, Del Giacco L, Elariny H, Van Meter A, Younoszai A, Goodman Z, Baranova A, Christensen A, Grant G, Chandhoke V. Younossi ZM, et al. Liver Int. 2005 Aug;25(4):760-71. doi: 10.1111/j.1478-3231.2005.01117.x. Liver Int. 2005. PMID: 15998427

10

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. Younossi ZM, et al. Hepatology. 2005 Sep;42(3):665-74. doi: 10.1002/hep.20838. Hepatology. 2005. PMID: 16116632

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

626 results

Search Page